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The use ofpesticides in agriculture and the
release ofchemical compounds from manu-
facturing industries are common in south-
ern Europe. Evidence of the estrogenic
effects of some pesticides (1), alkylphenols
(2), and plastic monomers (3) has raised
concerns about environmental contamina-
tion by these chemicals. We became inter-
ested in the use of an estrogenicity test to
assess the environmental and human health
effects ofestrogenic xenobiotics and to dis-
criminate between estrogenic and nonestro-
genic chemicals. Tests based on increased
mitotic activity in tissues ofthe genital tract
of female rodents after administration of
chemicals have been proposed (4); but,
although reliable, these methods are not
suitable for large-scale screening ofsuspect-
ed estrogenic chemicals or for measuring
the total estrogenic burden in human sam-
ples. We therefore adopted the biologically
equivalent, easily performed E-screen assay
described by Soto et al. (5). This bioassay
compares the cell yield between cultures of
breast tumor-derived MCF7 cells treated
with estradiol and cultures treated with dif-
ferent concentrations of xenobiotics sus-
pected ofbeing estrogenic.
MCF7 cells were recommended as target
cells because of their widely acknowledged
estrogen-sensitivity (6).This cell line was ini-
tially established by Soule et al. (7) from a
metastatic pleural effusion from a post-
menopausal patient with metastatic, infil-
trating ductal carcinoma of the breast: the
patient was previously treated with radio-
therapyand hormones. Although long-term
established MCF7 cells are usedworldwide,
several MCF7 cell stocks with different sen-
sitivities to estrogens have been developed
during the last 20 years (8).
The purpose ofthis study was to char-
acterize the response of four MCF7 cell
stocks routinely held by different laborato-
ries to assess which of them performs best
in the E-screen test. We investigated the
proliferative pattern and rate of estrogen-
induced synthesis ofcell type-specific pro-
teins and the effects ofp-nonyl-phenol and
bisphenol-A on the four cell stocks.
Methods
Cell lines and cell culture conditions. Four
stocks of MCF7 cells were used: MCF7
BUS cells were a gift from C. Sonnenschein
(Tufts University, Boston), who cloned the
cells (C MCF7) from passage 173 of the
originai7 MCF7 cells, received from C.
McGrath of the Michigan Cancer Found-
ation; they were at post-cloning passages
70-103 at the time of our study. MCF7
ATCC cells at passage 147 were from the
American Type Culture Collection (freeze
no. 8655). MCF7 BB cells used at passages
580 to 595 were obtained in 1984 from G.
Leclercq (Institut Jules Bordet, Brussels,
Belgium), who received them from M. Rich
ofthe Michigan Cancer Foundation. MCF7
BB104 cells were derived in our laboratory
from MCF7 BB cells bykeeping them in an
estrogen-free medium for more than 24
months and were used at passages 12 to 21.
For routine maintenance, cells were grown in
Dulbecco's modification of Eagle's medium
(DME) supplemented with 5% fetal bovine
serum (FBS; PAA Labor und Forschungs
Ges, MBH, Linz, Austria) in an atmosphere
of5% C02/95% air under saturating humidi-
ty at 37°C, except for MCF7 cells BB104,
which were routinely maintained in 10%
charcoal dextran-treated human serum
(CDHS)-supplemented phenol red-free
DME medium, prepared as described below.
Plasma-derived human serum was pre-
pared from expired plasma by adding calci-
um chloride to a final concentration of 30
mM to facilitate clot formation. Sex steroids
were removed from serum by charcoal-dex-
tran stripping (6).
Cellproliferation experiments. We used
MCF7 cells in the E-screen test according to
a technique slightly modified from that orig-
inally described by Soto et al. (5). Briefly,
cells were trypsinized and plated in 24-well
plates (Limbro, McLean, Virginia) at an ini-
tial concentration of 10,000 cells per well in
5% FBS in DME. BB104 cells were seeded
in 10% CDHS supplemented medium. The
cells were allowed to attach for 24 hr, then
10% CDHS-supplemented phenol red-free
DME was substituted for the seeding medi-
um. A range of concentrations of the test
compound were added, and the assay was
stopped after 144 hr by removing the medi-
um from wells, fixing the cells, and staining
them with sulforhodamine-B (SRB).
The fixation and staining technique was
modified from that described by Skehan et
al. (9). Briefly, cells were treated with cold
10% trichloracetic acid and incubated at
4°C for 30 min. Then the cells were washed
five times with tap water and left to dry.
The fixed cells were stained for 10 min with
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0.4% (w/v) SRB dissolved in 1% acetic
acid. Wells were rinsed with 1% acetic acid
and air dried. Bound dye was solubilized
with 10 mM Tris base (pH 10.5) in a shak-
er. Finally, aliquots were transferred to a
96-well plate to be read in a Titertek
Multiscan apparatus (Flow, Irvine,
California) at 492 nm. We evaluated lin-
earity of the SRB assay with cell number
for each MCF7 cell stock before each cell-
growth experiment. Alternatively, cells
were lysed and nuclei counted on a ZM
Coulter Counter apparatus (Coulter
Electronics, Luton, England) according to
a previously described technique (6).
We used the E-screen test to determine,
for all four MCF7 cell stocks, the relative
proliferative potency (RPP), defined as the
ratio between the minimum concentration
of estradiol-17f7 needed for maximal cell
yield and the minimum dose of the test
compound needed to obtain a similar
effect, and the relative proliferative effect
(RPE); that is, the ratio between the high-
est cell yield obtained with the chemical
andwith estradiol-17f3 x 100 (5).
Results are expressed as the means plus
or minus standard deviations. In prolifera-
tion yield experiments, each point is the
mean of three counts from four culture
wells. Mean cell numbers were normalized
to the steroid-free control, equal to 1, to
correct for differences in the initial plating
density. Differences between the diverse
groups were calculatedwith Student's S-test.
Estrogen andprogesterone receptormea-
surements. We seeded MCF7 cells in T-25
flasks in 5% FBS-supplemented DME. The
next day, the medium was changed to 10%
CDHS-supplemented DME medium, and
estradiol-17l3 or the chemicals to be tested
were added. One group of cells received
vehicle alone. After 72 hr, the culture medi-
um was discarded and cells were frozen in
liquid nitrogen. To extract receptor mole-
cules, cells were incubated at 40C for 30
min with 1 mL of extraction buffer (0.5M
KCI, 10 mM potassium phosphate, 1.5
mM EDTA, and 1 mM monothioglycerol,
pH 7.4) according to a previously described
technique (10). The cell debris were pellet-
ed, and estrogen receptors and progesterone
receptors were measured in a 100-1tL
extract aliquot by enzyme immunoassay
using the Abbott estrogen receptor and
progesterone receptor-enzyme immunoas-
say monoclonal kits (Abbott Diagnostic,
Wiesbaden, Germany) according to the
manufacturer's instructions.
Cell type-specific proteins and com-
pounds tested. Cathepsin-D and pS2 pro-
teins were measured in culture media with
the ELSA-CATH-D and ELSA-pS2
immunoradiometric assays (CIS Biolnter-
Table 1. Cell cycle distribution and estimated doubling time(TD) ofthe four MCF7 cell stocksa
Distribution (% total cells)
Treatment/stock G0/G1 S G2/M TD(hrl
10% FBS-DME
MCF7 BUS 69.0 ± 2.6 19.2 ± 2.1 11.9 ± 1.4 32± 1.7
MCF7 ATCC 59.4 ± 3.9 32.4 ± 3.6 7.4 ± 2.5 49 ± 2.7
MCF7 BB 66.2 ±3.4 22.3 ± 1.8 11.5 ± 1.6 27± 1.7
CDHS-PhR-DME
MCF7 BUS 93.5 ±4.2 4.0± 1.2 2.6± 0.5 46± 3.0
MCF7ATCC 68.1 ±4.7 19.7±3.0 12.9±2.0 59±3.1
MCF7 BB104 60.8± 4.1 36.6 ± 2.7 4.2 ± 1.9 37 ± 2.2
Abbreviations: FBS, fetal bovine serum; DME, Dulbecco's modification of Eagle's medium; CDHS, charcoal
dextran-treated human serum; PhR, phenol red-free.
aAll data are means ± SD of at leastthree separate determinations.
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Figure 1. Growth curves of MCF7 cells cultured in the presence of 10% fetal bovine serum (FBS), 10%
charcoal dextran-treated human serum (CDHS), or 10% CDHS plus 1 nM estradiol-171 (CDHS + E2). Each
point is the mean of three counts from four culture wells; bars indicate SDs. (A) BUS cells, (B) BB cells,
(C)ATCC cells,(D) BB104 cells.
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national, Gif-sur-Yvette, France). The cul-
ture medium was centrifuged at 1000g for
10 min to eliminate floating and detached
cells. Samples were kept frozen at -800C
until the assays were done.
Estradiol-1713 was obtained from Sigma
(St. Louis, Missouri). Bisphenol-A (BPA)
and p-nonyl-phenol (NP) were obtained
from Aldrich-Chemie (Albuch, Germany).
Chemicals were dissolved in ethanol to a
final concentration of 1 mM and stored at
-20°C; all were diluted in phenol red-free
DME immediately before use. The final
ethanol concentration in the culture medi-
um did not exceed 0.1%.
Flow cytometry studies. MCF7 cells
grown in 10% FBS-supplemented DME
medium were seeded by quintuplicate in T-
25 flasks. Cells were harvested and processed
during the exponential growth phase for
cytometry analysis (11). Briefly, cells were
incubated at 40C for 30 min in darkness in
Vindelov's solution containing RNAse and
propidium iodide. The cell cycle was deter-
mined in an Ortho Cyteron Absolute flow
cytometer (Ortho Diagnostic, Raritan, New
Jersey), using the "cell cycle" program to cal-
culate the proportions of cells in different
phases ofthe cycle. As an internal DNA ref-
erence, stained chicken blood cells were
added to each sample. Alternatively, MCF7
cells were grown in 10% CDHS-supple-
mentedphenol red-free medium in the pres-
ence of 10 nM estradiol or its vehide for 72
hr before harvesting, then processed as
describedabove.
Results
Growth Characteristics and Light
Microscopy
The four MCF7 cell stocks differed in their
staining with SRB; we therefore evaluated
the relationship between optical density
(OD) and cell number separately for each
stock. The least-square linear correlation
coefficients for the relation between OD
and cell number were 0.998 for BB, 0.996
for BB104, 0.996 for BUS, and 0.996 for
the ATCC stock. From the best-fit parame-
ters, we estimated the correleation between
cell number and OD by solving the follow-
ing equations: MCF7 BB cell number =
[(1.5 x 10-6) x OD] + 0.038; MCF7
BB104 cell number = [(1.38 x 10-6) x OD]
+ 0.040; MCF7 BUS cell number = [(1.31
x 10-6) x OD] + 0.048; and MCF7 ATCC
cell number = [(2.45 x 10-6) x OD] +
0.020. Sulforhodamine-B staining was
clearly more intense in MCF7 ATCC cells
than in the other three cell stocks.
We measured the growth rate and cell
cycle distribution for MCF7 cells grown in
10% FBS-supplemented DME medium.
Table 1 shows the distribution ofphases in
the cell cycle and the estimated doubling
time (1TD) for all clones studied.
MCF7 BUS and ATCC cells were easi-
lydistinguishable from BB and BB104 cells
by light microscopy. The first two stocks
had rounded edges, and were smaller and
more refractive than the latter two. Cells
from BB and BB104 stocks had extensive
intercellular contacts, showed greater cell
density at confluence, and attached more
strongly to the plastic surfaces.
Proliferative Patterns
MCF7 cells maintained for 6 days in 10%
CDHS-supplemented DME behaved dif-
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ferently depending on the stock tested.
MCF7 BUS cells underwent two doublings
and then stopped proliferating. In contrast,
the other three MCF7 clones either slowed
their proliferation rate (MCF7 BB104 and
BB cells) or were not disturbed at all
(MCF7ATCC cells) in estrogen free-medi-
um (Fig. 1). Flow cytometry studies con-
firmed the high proportion of arrest in
MCF7 BUS cells cultured for 72 hr in
estrogen-depleted medium. Switching
ATCC cells to an estrogen-free medium
did not significantly modify the distribu-
tion ofcell cycle phases (Table 1).
The addition of estradiol-17g to
CDHS-supplemented medium increased
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Figure 2. Cell proliferation yields of MCF7 cells. (A) BUS, (B) BB, (C) ATCC, and (D) BB104 cell stocks grow-
ing in 10% charcoal dextran-treated human serum supplemented medium were exposed for 144 hr to dif-
ferent amounts of estradiol-17i (E2), p-nonyl-phenol (NP), and bisphenol-A (BPA). Each point is the mean
ofthree countsfrom four culture wells; bars indicate SDs.
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cell yields in all MCF7 stocks. In MCF7
BUS cells, the proliferative effect was great-
est with .0.01 nM estradiol-17B (Fig. 2).
The cell yield was sixfold greater than in
controls (6.67 ± 1.21; p < 0.001).
Estradiol-17B79 also increased cell yield in
BB and BB104 cells by up to twofold com-
pared to controls (p < 0.05). In ATCC
cells, the effect ofestradiol-17B was almost
negligible (<1.5-fold increase, not signifi-
cant). As expected from the preceding data,
estradiol-17B treatment also modified the
proliferation of these cells differently.
When 0.1 nM estradiol-17B was added to
10% CDHS-supplemented DME medi-
um, MCF7 BUS cells showed the shortest
doubling time (TD = 21 ± 3.8 hr) and
ATCC cells the longest TD (54 ± 4.2 hr).
In all cell stocks, NP and BPA increased
cell yields to values similar to those
obtained with estradiol-17B. However, NP
and BPA were much less potent than estra-
diol-17B (i.e., MCF7 BUS cells showed
maximal proliferation at concentrations of
nonylphenol of 10 nM and higher (Fig. 2).
The RPPvalues areshown inTable 2.
We also studied the response ofMCF7
cells to estradiol-17g in medium supple-
mented with different amounts of serum.
MCF7 BUS and BB104 cells were cultured
in DME medium with 5-50% CDHS.
Figure 3 shows the effect of 0.1 nM estra-
diol-17g on cell yield. In MCF7 BB104
cells; estradiol-17B consistently increased
proliferation (approximately twofold over
control values), regardless ofthe concentra-
tion of CD serum added. In MCF7 BUS
cells, differences in cell yield between estra-
diol-17g-treated and nontreated cells
decreased as the concentration of serum
increased. The effect of 0.1 nM estradiol-
17B was maximal when 10% serum was
added to the medium. At 50% of serum
replacement, 0.1 nM estradiol-17f3 had no
apparent effect on MCF7 BUS cells.
Cathepsin-D and pS2 Secretion
Cathepsin-D and pS2 protein accumula-
tion in the culture medium reflected
increases in cell number (Fig. 4). MCF7
BB and BB104 cells secreted the largest
amounts ofpS2 after 144 hr ofsubculture
in estrogen-free medium (BB, 508 ± 101
ng/106cells; BB104 612 ± 133 ng/106 mil-
lion cells). Estradiol had little effect on the
secretion of pS2 in both cell stocks (-1.7
increase over control values in BB104).
However, pS2 secretion by MCF7-BUS
cells was significantly increased by concen-
trations ofestradiol-17g 0.1 nM and high-
er (-3.5-fold increase over controls).
Interestingly, MCF7-BUS cells showed the
lowest basal levels (53.9 ± 16.7 ng/106
cells) of protein secretion and the greatest
effect of estradiol-17R on pS2 secretion
(Fig. 4A). Differences in cathepsin-D pro-
tein secretion between the four MCF7 cell
stocks were smaller; basal levels ranged
from 8.9 ± 4.0 pmol/106 cells in the BUS
stock to 19.5 ± 7.8 pmol/106 cells in the
BB104 clone. Estradiol-17B treatment
slightly increased cathepsin-D accumula-
tion in the culture medium. The greatest
effect was seen in BB cells, in which 1 nM
estradiol-17f3 raised cathepsin-D protein
levels 1.8-fold (Fig. 4B).
Table2. Estrogenic response of MCF7 cellsto estradiol-178 (E2), p-nonylphenol (NP) and bisphenol-A
(BPA)
Cell stock Compound Concentration (nM)8 PEb RPE(%)c RPP(%)d
BUS E2 0.01 6.7 100 100
NP 10 6.8 103 0.001
BPA 100 6.3 97 0.0001
ATCC E2 0.01 1.6 100 100
NP 100 1.6 100 0.0001
BPA 100 1.5 95 0.0001
BB E2 0.01 2.2 100 100
NP 100 2.0 95 0.0001
BPA 1000 1.9 90 0.00001
BB104 E2 0.01 2.3 100 100
NP 100 2.1 98 0.0001
BPA 1000 2.1 98 0.00001
"Lowest concentration needed for maximal cellyield.
bProliferative effect: ratio between the highest cell yield obtained with the chemical and the hormone-
free control.
cRelative proliferative effect: (PE ofthetest compound/PE ofE2) 100.
dRelative proliferative potency: (dose of E2/dose of test compound needed to produce maximal cell
yield)100.
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Figure 3. Effect of increasing concentrations of charcoal dextran-treated human serum on the growth of
MCF7 (A) BUS and (B) BB104 cells. MCF7 cells were grown for 6 days in estrogen-depleted medium sup-
plemented with different concentrations of charcoal dextran-treated human serum (from 5% to 50% as
indicated along the X-axis). Estradiol-17g (0.1 nM) was added to cultures (E2); controls (C) received vehi-
cle alone.
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Figure 4. pS2 (A) and cathepsin-D (B) accumulated in the culture medium. MCF7 BUS, ATCC, BB, and
BB104 cell stocks were grown in 10% charcoal dextran-treated human serum-supplemented medium (C)
and exposed for 144 hr to 1 nM estradiol-17B (E2). *Values significantly different from control (p < 0.05).
Bars indicate SDs.
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Hormone Receptors
MCF7 cells bear receptors for estradiol-17f
and progesterone. The highest value for
estrogen receptor (400 ± 55 fmol/mg pro-
tein) was found in the BB104 stock; these
cells are routinely kept in estrogen-free
medium. In BUS cells, estrogen receptor
expression was 183 ± 29 fmol/mg of
extracted protein. Treatment with estradiol-
17f3 decreased estrogen receptor levels and
increased progesterone receptor levels. The
lowest basal progesterone receptor value
(7.9 ± 1.3 fmol/mg protein), which
approached the lower limit of detection of
the monoclonal antibody assay, was
observed in the MCF7 BUS stock, which
also showed the largest estradiol-mediated
increase in progesterone receptor (-12-fold
increase) (Fig. 5). Basal levels of proges-
terone receptor were 24 ± 7, 75 ± 12, and
83 ± 7 fmol/mg of protein in BB104, BB,
and ATCC cells, respectively. In all the
three stocks, estradiol-17f3 increased proges-
terone receptor levels in a dose-dependent
manner; however, the effect was smaller
than that observed in BUS cells (Fig. 5).
We did another set of experiments to
investigate the effect of estrogens on the
"disappearance" of estrogen receptors
(Table 3). In cells treated for 72 hr, estradi-
ol-17I3 significantly increased progesterone
receptor and decreased estrogen receptor
concentrations. When MCF7 BUS cells
were treated with concentrations of >100
nM NP there was a significant increase in
progesterone receptor (Table 3). Treatment
with BPA also increased progesterone
receptor, but the effect was weaker at high-
er concentrations (>1000 nM). However,
estrogen receptor levels were unchanged
when the medium contained NP or BPA.
Discussion
A bioassay can be effectively assessed only
with the help ofa standardized set ofpara-
meters that measure reproducibility. In
evaluations ofthe E-screen test, uniformity
of the MCF7 cell stock used is the most
important variable that affects repro-
ducibility.
The four MCF7 cell stocks we assayed
were distinguishable on the basis of their
biological behavior. In the absence ofestro-
gen, MCF7 BUS cells stopped proliferat-
ing; they accumulated in theGO/GI phase,
estrogen receptor receptor levels increased,
progesterone receptor decreased, and low
levels ofpS2 protein were secreted. Ofthe
MCF7 stocks we tested, MCF7 BUS cells
showed the highest proliferative response to
estradiol-17f, with cell yields increasing up
to sixfold over nontreated cells in a 144-hr
period. This increase was ofthe same order
of magnitude as that described previously
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Figure 5. Estrogen and progesterone receptors in MCF7 cells: (A) BUS, (B) BB, (C) ATCC, (D) BB104. Cells
in T-25 flasks were incubated in 10% charcoal dextran-treated human serum for 72 hr with 1 nM of estra-
diol-171 (E2). Controls received the vehicle alone. Estrogen receptors (ER) and progesterone receptors
(PR) were measured in the extracted cells with the monoclonal antibody technique as deccribed in
Methods. Results are expressed asfemtomole per milligram of extracted protein ± SD (bars). *Values sig-
nificantly differentfrom control (p<0.05).
in monolayer cultures of MCF7 cells
(5,12-16).The other three cell stocks
responded to estradiol-17f with a much
smaller increase in cell yield, which was
never higher than twofold over control val-
ues. Similar proliferative responses were
reported in MCF7 cell stocks tested in
media supplemented with different
amounts ofcharcoal dextran serum, which
ranged from 20% to 0.5% (17-30), and in
serumless medium (31-33). Poor prolifera-
tive responses to estradiol-17t3 were
described when nonstripped, serum-sup-
plemented mediawere used (34-36).
Differences in culture condition
(29-37, the type of serum-supplemented
medium (17,18), serum lots (17), the pres-
ence ofphenol red (38), insulin (27,39,40),
cell passage (41), and cell density or culture
matrices (20,33,41), may explain the poor
proliferative effect ofestradiol-1711 in some
MCF7 cell stocks. The disparate effects of
estradiol-17f1, other so-called mitogens,
and growth inhibitors on cell proliferation
have also been attributed to heterogeneity
of the undoned cells (39,42,43) or to dif-
ferences in the MCF7 cells used
(8,13,16,25,44,45). The four cell stocks we
assayed were cultured in the same medium
(phenol red-free DME), which was supple-
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Table 3. Effect (means ± SD) of estradiol-17B (E2),
p-nonyl-phenol (NP), and bisphenol-A (BPA) on
estrogen and progesterone receptors in MCF7
BUS cell stock
fmol receptor/mg
extracted protein
Concentration Estrogen Progesterone
(nM) receptors receptors
Control 174 ± 12 (1O0)a 17 ± 12(100)
E2 0.1 195 ± 35(112) 131 ± 12(770)*
1 91 ± 11 (52)* 202±21 (1188)*
10 87 ± 15 (50)* 211 ± 15(1241*
100 87± 07 (50)* 154± 70(906)*
NP 1 179 ± 30(103) 23± 10(135)
10 207 ± 12(119) 29± 13 (171)
100 189 ± 15 (109) 161 ±35 (575)*
1000 164± 13(94) 191 ± 11 (1123)*
BPA 1 164 ± 10 (94) 23± 21 (135)
10 229 ± 18 (132) 23± 12(135)
100 228 ±30(131) 56 ± 33(329)
1000 167 ± 18(96) 167 ± 21 (982)*
"Numbers in parentheses are the percentage of
variation versus controls.
*Values significantly different from control (p <
0.05).
mented with equal concentrations of
human serum (10%) from the same source
(healthy voluntary donors). Experiments
with all four cell stocks were always run in
parallel. Obviously, we could not use exact-
ly the same number of passages (41).
Nevertheless, MCF7 BUS cells, which
showed the greatest proliferative response
to estradiol-179, were at passage 100 (+173
passages before cloning) and MCF7 ATCC
cells, which showed the poorest response to
estradiol-17I9, were at a similar number of
passages (received at passage 148, tested
after 150-170 passages in our laboratory).
Our results therefore suggest that differ-
ences in the response cannot be attributed
to culture conditions or to passage number.
In experiments designed to test the
influence of serum concentration on the
effect of 17g-estradiol, serum seemed to
counteract the effect of estradiol-17f in
MCF7 BUS cells. Increasing serum con-
centration from 5% to 50% reduced cell
yield despite the presence of 0.1 nM of
estradiol-17f7. We found it necessary to
increase the concentration of estradiol-17B
to maintain the differences between treated
and nontreated cells as serum supplementa-
tion increased.
Differences in cell yield between estra-
diol-17f9-treated and nontreated cultures
were significantly higher in cell stocks that
showed arrest of growth in serum-supple-
mented, estrogen-free medium. The differ-
ences between estrogen-supplemented and
nonsupplemented MCF7 BUS cells were
mostly due to arrest in GO/GI mediated by
CD serum in the absence of estrogen
(Table 1).
The minimal effect ofestradiol-17g on
MCF7 ATCC cell yields was notable; simi-
lar results have been described by others
(30,32,35). Because ATCC cells are from a
different patient than the one from which
MCF7 cells originated (8), this stock
should be used with caution in cell prolif-
eration tests such as the E-screen bioassay.
Estradiol-17g affected MCF7 BUS cell
yield, cell cycle distribution, and specific
protein synthesis. In this stock, the hor-
mone reduced estrogen receptor content,
increased the amount of measurable prog-
esterone receptor, and increased pS2 pro-
tein secretion. We found no significant
effect ofestradiol-179 on cathepsin-D pro-
tein synthesis (25). Although some MCF7
cell stocks respond to estradiol-17f3 with a
higher increase in cathepsin-D protein
secretion than others (46), all four MCF7
cell stocks tested here showed the same
poor response. In MCF7 BUS cells, the
presence of estradiol-17g in the culture
medium had a net stimulatory effect on
pS2 protein production, mainly because of
the low amounts ofthis protein secreted in
estrogen free-medium.
p-Nonyl-phenol and BPA were found
to be estrogenic, increasing cell yield and
progesterone receptor concentration in
MCF7 cells (2,3,47). These compounds
mimicked the proliferative effect ofestradi-
ol-179 and increased progesterone receptor
levels, albeit to a lower extent than did the
hormone. However, the effects ofestradiol-
17f3 and these chemicals on the disappear-
ance of estrogen receptor differed. An
increase in progesterone receptor levels was
not associated with estrogen receptor
downregulation. Interestingly, Schutze et
al. (19) showed that catecholestrogens,
which increase the rate of MCF7 cell pro-
liferation and progesterone receptor levels,
evoked estrogen receptor processing only
during the first 8 hr after treatment; there-
after, estrogen receptor increased, reaching
basal levels at 24 hr. We are now investi-
gating whether differences in the ability to
evoke processing are due to an early phe-
nomenon occurring before 72 hr, when
estrogen receptor was routinely evaluated,
or whether these differences are related to
the use ofexchange assays or the immuno-
logical detection ofestrogen receptor (48).
Validation of the RPE and RPP ofthe
chemicals tested here seems to depend on
the cell stocks used in the E-screen bioas-
say. Although RPE was only slightly differ-
ent in MCF7 BUS, BB, and BB104 cells, it
may not be easy to detect partial estrogen
agonists with cells other than BUS. The
differences of less than twofold between
estradiol-17g-treated cells and controls
when MCF7 BB, BB1O4, and ATCC cells
were used defined a narrow range ofsensi-
tivity. It seems evident that the limited
ability of BB and BB104 cells to grow in
the presence of NP and BPA resulted in
underestimation of RPP. The ATCC cell
stock seems to be the least appropriate for
both purposes.
In summary, it is now clear that induc-
tion ofcell proliferation is the hallmark of
estrogen action. The effects ofestrogens on
cell type-specific protein synthesis (whether
induction or downregulation) and cell
hypertrophy are variable and may be
evoked by nonestrogenic agents. Our
results suggest that the ability of estrogens
to make cells proliferate can be proved in
vitro using an appropriate bioassay such as
the E-screen test. MCF7 BUS cell stocks
and others showing a similar proliferative
pattern should be chosen for use in the E-
screen test, or whenever a proliferative
effect ofestrogen is to be demonstrated.
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"Mechanisms and Prevention of Environmentally Caused Cancers", a symposium presented by The Lovelace
Institutes, will be held October 21-25, 1995, in Santa Fe, New Mexico. The purpose of this symposium is to promote collabo-
rationbetween scientists interested in thebasic mechanisms ofenvironmentally-caused cancer and investigators focusing on
preventing cancer development with chemo-intervention strategies. Dr. Bruce Ames (University of California) will be the
keynote speaker. Other speakers include Dr. Eric Stanbridge (UC Irvine), Dr. Stephen Friend (Harvard), and Dr. Gary Stoner
(Ohio State University).
For further information, please contact:
Alice M. Hannon, The Lovelace Institutes, 2425 Ridgecrest Drive S.E., Albuquerque, NM 87108-5127
850 Volume 103, Number9, September 1995 * Environmental Health Perspectives